<DOC>
	<DOCNO>NCT01372345</DOCNO>
	<brief_summary>The purpose study compare relative bioavailability ciprofloxacin 1000 mg ER tablets Dr.Reddy 's CIPRO® XR 1000 mg Bayer Pharmaceuticals Corporation healthy , adult , non-smoking subject fast condition .</brief_summary>
	<brief_title>Bioavailability Study Ciprofloxacin 1000 mg ER Tablets Dr. Reddy 's Under Fasting Conditions</brief_title>
	<detailed_description>This single dose , randomize , two-period , two-treatment , two sequence crossover study conduct compare relative bioavailability ciprofloxacin 1000 mg ER tablet Dr. Reddy 's CIPRO® XR 1000 mg Bayer Pharmaceuticals Corporation fast condition .</detailed_description>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>1 . Noninstitutionalized subject consist member , coInmunity large . 2 . All subject select study nonsmoker 18 45 year age ( inclusive ) . Female subject must unable become pregnant ( postmenopausal least 1 year , surgically sterile ) 3 . Each subject shall give , general physical examination within 28 day initiation study include , limited , blood pressure , general observation , history . 4 . Each female subject give serum pregnancy test part prestudy screen process . 5 . Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement . 6 . Electrocardiograms participate subject record initiation study file subject 's case report form . 1 . Subjects history alcoholism drug addiction ( past 2 year ) , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis glaucoma eligible study . 2 . Subjects whose clinical laboratory test value outside normal range may retested discretion clinical investigator . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . 3 . Subjects history allergic response class drug test exclude study . 4 . All subject urine / saliva sample assay presence drug abuse part clinical laboratory screening procedure checkin dose period . Subjects find urine/saliva concentration test drug allow participate . 5 . Subjects donate blood / plasma least thirty ( 30 ) day prior tile first dose study . 6 . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate . 7 . Female subject pregnant able ( woman childbearing potential ) become pregnant study allow participate . 8 . All female subject screen pregnancy checkin study period . Subjects positive inconclusive result withdrawn study . 9 . Subjects history clinically significant illness surgery within 4 week prior administration study medication eligible study . 10 . Subjects BMI ≥30.0 Kg/m2 eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>